GeurtsJJCalabreseMFisherE. Measurement and clinical effect of gray matter pathology in multiple sclerosis. Lancet Neurol2012; 11: 1082–1092.
2.
SawcerSHellenthalGPirinenM. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature2011; 476: 214–219.
3.
SkripuletzTManzelAGropengießerK. Pivotal role of choline metabolites in remyelination. Brain2014Dec.17. pii: awu358.
4.
KnippenbergSSkripuletzTRathKJ. CDP-choline is not protective in the SOD1-G93A mouse model of ALS. Amyotroph Lateral Scler Frontotemporal Degener2013; 14: 284–290.
5.
OvergaardK. The effects of citicoline on acute ischemic stroke: A review. Stroke Cerebrovasc Dis2014; 23: 1764–1769.
6.
QianKGuYZhaoY. Citicoline protects brain against closed head injury in rats through suppressing oxidative stress and calpain over-activation. Neurochem Res2014; 39: 1206–1218.
7.
GriebP. Neuroprotective properties of citicoline: Facts, doubts and unresolved issues. CNS Drugs2014; 28: 185–193.
8.
ChatawayJSchuererNAlsanousiA. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): A randomised, placebo-controlled, phase 2 trial. Lancet2014; 383: 2213–2221.
9.
AndersonVMBartlettJWFoxNC. Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: Sample size estimates. J Neurol2007; 254: 1588–1594.
10.
NakamuraKGuizardNFonovVS. Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis. Neuroimage Clin2013; 4: 10–17.
11.
SalzerJSvenningssonASundströmP. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler2010; 16: 287–292.
12.
TrentiniAComabellaMTintoréM. N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. J Neurol2014; 261: 2338–2343.
